Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (316) 316
Newspaper Article (86) 86
Publication (39) 39
Magazine Article (7) 7
Book Chapter (6) 6
Book / eBook (5) 5
Conference Proceeding (4) 4
Book Review (3) 3
Newsletter (2) 2
Patent (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (142) 142
multiple sclerosis (105) 105
clinical neurology (86) 86
male (84) 84
female (79) 79
adult (78) 78
index medicus (68) 68
middle aged (66) 66
neurosciences (58) 58
magnetic resonance imaging (57) 57
mri (34) 34
brain - pathology (32) 32
article (31) 31
animals (28) 28
radiology, nuclear medicine & medical imaging (26) 26
double-blind method (24) 24
treatment outcome (24) 24
brain (23) 23
adolescent (22) 22
disability (22) 22
disease progression (22) 22
multiple sclerosis - pathology (22) 22
neurology (22) 22
multiple sclerosis, relapsing-remitting - drug therapy (21) 21
magnetic resonance imaging - methods (20) 20
young adult (20) 20
clinical trials (19) 19
glatiramer acetate (19) 19
multiple sclerosis - diagnosis (19) 19
double-blind (18) 18
multiple-sclerosis (16) 16
abridged index medicus (15) 15
disability evaluation (15) 15
disease (14) 14
multiple sclerosis, relapsing-remitting - pathology (14) 14
neuroimaging (14) 14
segmentation (14) 14
immunosuppressive agents - therapeutic use (13) 13
multiple sclerosis - physiopathology (13) 13
trial (13) 13
aged (12) 12
drug therapy (12) 12
laws, regulations and rules (12) 12
multiple sclerosis - drug therapy (12) 12
peptides - therapeutic use (12) 12
rubella virus - immunology (12) 12
white-matter (12) 12
administration, oral (11) 11
atrophy (11) 11
care and treatment (11) 11
dose-response relationship, drug (11) 11
image processing, computer-assisted (11) 11
interferon beta-1a (11) 11
lesions (11) 11
multicenter (11) 11
recurrence (11) 11
reproducibility of results (11) 11
time factors (11) 11
medicine, general & internal (10) 10
mice (10) 10
multiple sclerosis, chronic progressive - drug therapy (10) 10
algorithms (9) 9
crotonates - administration & dosage (9) 9
diagnosis (9) 9
efficacy (9) 9
encephalitis - pathology (9) 9
ms (9) 9
oral teriflunomide (9) 9
patients (9) 9
placebo-controlled trial (9) 9
safety (9) 9
sensitivity and specificity (9) 9
severity of illness index (9) 9
teriflunomide (9) 9
toluidines - administration & dosage (9) 9
antibodies, viral - analysis (8) 8
california (8) 8
cells, cultured (8) 8
cerebrospinal fluid (8) 8
child (8) 8
clinical trial (8) 8
gadolinium (8) 8
interferon (8) 8
legislators (8) 8
magnetic resonance spectroscopy (8) 8
multiple sclerosis - diagnostic imaging (8) 8
multiple sclerosis, relapsing-remitting - diagnosis (8) 8
nuclear magnetic resonance--nmr (8) 8
ocrelizumab (8) 8
amino acid sequence (7) 7
brain atrophy (7) 7
cognitive impairment (7) 7
immunology (7) 7
intracortical lesions (7) 7
inversion-recovery (7) 7
molecular sequence data (7) 7
multiple sclerosis - immunology (7) 7
pathology (7) 7
predictive value of tests (7) 7
research article (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Multiple sclerosis
by Wolinsky, Jerry S
2005, Neurologic clinics, Volume 23, no. 1., xvi, 306
Multiple sclerosis
Book
Details down arrow
2. Principles of treatments in multiple sclerosis
by Hawkins, Clive P and Wolinsky, Jerry S
2000, ISBN 075064270X, xi, 324
Multiple sclerosis | Treatment
Book
Details down arrow
3. Full Text Patient selection for trials
by Wolinsky, Jerry S
Multiple Sclerosis Journal, ISSN 1352-4585, 10/2017, Volume 23, Issue 12, pp. 1636 - 1641
The last several decades have witnessed considerable progress in our understanding of the pathogenesis, refining diagnostic criteria, and identifying therapies... 
progression | phenotypes | outcomes research | primary progressive multiple sclerosis | efficacy | Trial design | MULTICENTER | REVISIONS | CLINICAL-COURSE | NEUROSCIENCES | CLINICAL NEUROLOGY | PROGRESSIVE MULTIPLE-SCLEROSIS | DOUBLE-BLIND | DISABILITY | PLACEBO-CONTROLLED TRIAL | DIAGNOSTIC-CRITERIA | FINGOLIMOD | Neuroprotective Agents - therapeutic use | Clinical Trials as Topic | Multiple Sclerosis, Chronic Progressive - drug therapy | Humans | Patient Selection | Clinical trials | Neuroprotection | Multiple sclerosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
by Montalban, Xavier and Hauser, Stephen L and Kappos, Ludwig and Arnold, Douglas L and Bar-Or, Amit and Comi, Giancarlo and de Seze, Jérôme and Giovannoni, Gavin and Hartung, Hans-Peter and Hemmer, Bernhard and Lublin, Fred and Rammohan, Kottil W and Selmaj, Krzysztof and Traboulsee, Anthony and Sauter, Annette and Masterman, Donna and Fontoura, Paulo and Belachew, Shibeshih and Garren, Hideki and Mairon, Nicole and Chin, Peter and Wolinsky, Jerry S and ORATORIO Clinical Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 3, pp. 209 - 220
Patients with primary progressive MS who received the anti-CD20+ humanized antibody ocrelizumab were less likely to have clinical deterioration that was... 
CD20 | MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | DEMYELINATION | DOUBLE-BLIND | CANCER-RISK | ANTIBODY | PATHOLOGY | DAMAGE | Antibodies, Monoclonal, Humanized - adverse effects | Brain - diagnostic imaging | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, CD20 | Double-Blind Method | Multiple Sclerosis, Chronic Progressive - immunology | T-Lymphocytes | Humans | Middle Aged | Male | Disease Progression | Young Adult | Magnetic Resonance Imaging | B-Lymphocytes - immunology | Adolescent | Infusions, Intravenous - adverse effects | Intention to Treat Analysis | Lymphocyte Count | Adult | Female | Multiple Sclerosis, Chronic Progressive - drug therapy | Neuroimaging | Multiple sclerosis | Intravenous administration | Pathogenesis | Clinical trials | Patients | Placebo effect | Magnetic resonance imaging | Lymphocytes B | Lymphocytes | Immunotherapy | Immunopathogenesis | Monoclonal antibodies | CD20 antigen | Respiratory tract diseases | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
by Lublin, Fred, Prof and Miller, David H, Prof and Freedman, Mark S, Prof and Cree, Bruce A C, Prof and Wolinsky, Jerry S, Prof and Weiner, Howard, Prof and Lubetzki, Catherine, Prof and Hartung, Hans-Peter, Prof and Montalban, Xavier, Prof and Uitdehaag, Bernard M J, Prof and Merschhemke, Martin, MD and Li, Bingbing, PhD and Putzki, Norman, MD and Liu, Fonda C, PharmD and Häring, Dieter A, PhD and Kappos, Ludwig, Prof and INFORMS Study Investigators and INFORMS study investigators
Lancet, The, ISSN 0140-6736, 03/2016, Volume 387, Issue 10023, pp. 1075 - 1084
Summary Background No treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator,... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | INTERFERON | REVISIONS | EFFICACY | FTY720 | DISABILITY | MODEL | NATURAL-HISTORY | BRAIN VOLUME LOSS | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Male | Treatment Outcome | Disease Progression | Dose-Response Relationship, Drug | Young Adult | Adolescent | Adult | Female | Aged | Multiple Sclerosis, Chronic Progressive - drug therapy | Immunosuppressive Agents - administration & dosage | Fingolimod Hydrochloride - administration & dosage | Phosphates | Clinical trials | Medical colleges | Multiple sclerosis | Research institutes | Sphingosine | Studies | Drug therapy | Neurodegeneration | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
by Confavreux, Christian, Prof and O'Connor, Paul, Prof and Comi, Giancarlo, Prof and Freedman, Mark S, Prof and Miller, Aaron E, Prof and Olsson, Tomas P, Prof and Wolinsky, Jerry S, Prof and Bagulho, Teresa, MD and Delhay, Jean-Luc, MD and Dukovic, Deborah, MS and Truffinet, Philippe, MD and Kappos, Ludwig, Prof and TOWER Trial Grp and TOWER Trial Group
Lancet Neurology, ISSN 1474-4422, 2014, Volume 13, Issue 3, pp. 247 - 256
Summary Background Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing–remitting multiple sclerosis. We aimed... 
Neurology | BG-12 | OUTCOMES | EFFICACY | SAFETY | III TRIAL | CLINICAL NEUROLOGY | Double-Blind Method | Administration, Oral | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Multiple Sclerosis, Relapsing-Remitting - diagnosis | Toluidines - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - epidemiology | Adult | Female | Crotonates - administration & dosage | Clinical trials | Medical colleges | Multiple sclerosis | Care and treatment | Voice recognition | Patient safety | Disease | Drug therapy | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
by Polman, C.H and Reingold, S.C and Banwell, B and Clanet, M and Cohen, J.A and Filippi, M and Fujihara, K and Havrdova, E and Hutchinson, M and Kappos, L and Lublin, F.D and Montalban, X and O'Connor, P and Sandberg-Wollheim, M and Thompson, A.J and Waubant, E and Weinshenker, B and Wolinsky, J.S and Lund University and Neurologi, Lund and Lunds universitet and Neurology, Lund
Annals of Neurology, ISSN 0364-5134, 2011, Volume 69, Issue 2, pp. 292 - 302
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of... 
RADIOLOGICALLY ISOLATED SYNDROME | SPINAL-CORD LESIONS | INTRACORTICAL LESIONS | DIFFERENTIAL-DIAGNOSIS | INVERSION-RECOVERY | NEUROMYELITIS-OPTICA | GENERAL NEUROLOGY PRACTICE | HIGH-FIELD MRI | CLINICALLY ISOLATED SYNDROMES | CORTICAL-LESIONS | NEUROSCIENCES | CLINICAL NEUROLOGY | Magnetic Resonance Imaging | Multiple Sclerosis - diagnosis | Early Diagnosis | Humans | Sensitivity and Specificity | Revisions | Multiple sclerosis | Older people | Rapid Communication | Neurologi | Clinical Medicine | Neurology | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
by Hauser, Stephen L and Bar-Or, Amit and Comi, Giancarlo and Giovannoni, Gavin and Hartung, Hans-Peter and Hemmer, Bernhard and Lublin, Fred and Montalban, Xavier and Rammohan, Kottil W and Selmaj, Krzysztof and Traboulsee, Anthony and Wolinsky, Jerry S and Arnold, Douglas L and Klingelschmitt, Gaelle and Masterman, Donna and Fontoura, Paulo and Belachew, Shibeshih and Chin, Peter and Mairon, Nicole and Garren, Hideki and Kappos, Ludwig and OPERA I OPERA II Clinical and OPERA I and OPERA II Clinical Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 3, pp. 221 - 234
In two trials involving patients with relapsing multiple sclerosis, the anti-CD20+ monoclonal antibody ocrelizumab was associated with lower annualized relapse... 
TRIAL | MEDICINE, GENERAL & INTERNAL | ANTIBODIES TARGETING CD20 | DEMYELINATION | RITUXIMAB | B-CELL DEPLETION | DISEASE | CANCER-RISK | DISABILITY | PATHOLOGY | PROSPECTS | Antibodies, Monoclonal, Humanized - adverse effects | Recurrence | Brain - diagnostic imaging | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, CD20 | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Disease Progression | Interferon-beta - therapeutic use | Magnetic Resonance Imaging | B-Lymphocytes - immunology | Interferon-beta - adverse effects | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Infusions, Intravenous - adverse effects | Adult | Female | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use | Multiple sclerosis | Intravenous administration | Lymphocytes B | Lymphocytes | β-Interferon | Immunotherapy | Clinical trials | Monoclonal antibodies | CD20 antigen | Gadolinium | Cognition | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights